Clinical trials: TACE
Hepatocellular Carcinoma
Drug-eluting Bead in Hepatocellular Carcinoma
In unresectable hepatocellular carcinoma, TACE using Lipiodol/anti cancer agent emulsion is the standard treatment and reported as a significantly better treatment through randomized comparison study like Llovet, etc.
- Trial name
- REDEBUT (NCT01332669)
- Testing
- DebDox TACE
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Carcinoma, Hepatocellular Carcinoma
The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study
To clarify the safety and efficacy of using uniform-sized drug-loaded embolic microspheres (E-TACE) of different particle sizes for graded embolization during TACE combined with Donafenib in the treatment of unresectable primary…
- Trial name
- NCT07180459
- Testing
- E-TACE, Donafenib
- Where
- 10 sites in China
- Volunteers
- 118 people
- Sponsor
- Xuhua Duan
Carcinoma, Hepatocellular
Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
REPLACE is a phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of regorafenib and pembrolizumab (Rego-Pembro) versus transarterial chemoembolization (TACE) or transarterial radioembolization…
- Trial name
- REPLACE (NCT04777851)
- Testing
- Regorafenib in combination with pembrolizumab, Loco-regional therapy
- Where
- 26 sites in United States, Belgium and 11 more
- Volunteers
- 45 people
- Sponsor
- Translational Research in Oncology
Hepatocellular Carcinoma
Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma
The goal of this prospective, interventional clinical trial is to evaluation of fruquintinib in combination with sintulimab and TACE for inoperable primary hepatocellular carcinoma for progression-free survival (PFS).
- Trial name
- NCT05971199
- Testing
- Fruquintinib, Sintilimab, Transcatheter arterial chemoembolization（TACE）
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients
This study is designed to evaluate the efficacy and safety of TACE combined with apatinib in treating advanced hepatocellular carcinoma.
- Trial name
- NCT02727309
- Testing
- Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Liver Neoplasms, Hepatocellular Cancer
Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)
This will be multicentre a phase II randomized controlled and open-label trial. It will compare the 6-months objective response (CR+PR) rates obtained with Drug Eluting Bead Trans-Arterial Chemo-Embolization (DEB-TACE) alone…
- Trial name
- HepSTAR (NCT02958163)
- Testing
- Trans-arterial Chemo-Embolization, Doxorubicin, Stereotactic Ablative Radiotherapy
- Where
- 5 sites in Belgium
- Volunteers
- 3 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization
Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge
The purpose of this study was to prospectively evaluate the efficacy and safety of TACE combined with MWA in patients with huge unresectable hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Microwave Ablation
- Trial name
- NCT03277716
- Testing
- TACE, MWA, MWA system
- Where
- 10 sites in China
- Volunteers
- 100 people
- Sponsor
- Fan Weijun
Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization
Estimation and Prediction of Individual Benefit From Postoperative Adjuvant Transcatheter Arterial Chemoembolization For Patients With Hepatocellular Carcinoma
Adjuvant transarterial chemoembolization (TACE) is widely adopted in China for resectable hepatocellular carcinoma (HCC), yet its efficacy remains inconsistent.
- Conditions
- Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Adjuvant Therapy, Machine Learning
- Trial name
- HCC (NCT07562763)
- Where
- China
- Volunteers
- 1,005 people
- Sponsor
- Anhui Provincial Hospital
Carcinoma, Hepatocellular
Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE
Background Hepatic intra-arterial chemoembolization (TACE) is proposed when potentially curative therapy (eg. surgical resection, percutaneous ablation)is no longer possible.
- Trial name
- PRECISION-IT (NCT00936689)
- Testing
- Selective TACE via microsphere loaded with Doxorubicin, Selective traditional TACE
- Where
- 5 sites in Italy
- Volunteers
- 178 people
- Sponsor
- Rita Golfieri
Hepatocellular Carcinoma
The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead
This study involves the combined use of the FDA approved device, LC Bead and the FDA approved drug, Doxorubicin for the treatment of primary hepatocellular carcinoma (HCC).
- Trial name
- NCT01259024
- Testing
- transarterial chemoembolization using a drug-eluting bead
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Carcinoma, Hepatocellular
Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCC
Transcatheter arterial chemoembolization (TACE) is a key palliative treatment for patients with inoperable hepatocellular carcinoma (HCC).
- Trial name
- NCT02338297
- Testing
- TACE, EGM, PVA
- Where
- 2 sites in China
- Volunteers
- 236 people
- Sponsor
- Nanjing Medical University
Liver Metastases, Colorectal Cancer
Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer
The trial is a randomized control trial. Patients are randomized between Ltx and other treatment that may include further chemotherapy, TACE, SIRT or other available treatment options.
- Trial name
- SECAIII (NCT03494946)
- Testing
- Liver transplantation, Chemotherapy
- Where
- Norway
- Volunteers
- 30 people
- Sponsor
- Oslo University Hospital
Hepatocellular Carcinoma, Rapamycin
Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC
To evaluate the clinical effect of rapamycin combined with TACE on early-stage HCC with overexpression of ASPH after radical surgery using randomized controlled study and provide a new anti-recurrence treatment for HCC patients…
- Trial name
- NCT02724332
- Testing
- Rapamycin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
The purpose of this study was to investigate the effect of only local radical treatment of liver metastases combined with systematic treatment in the treatment of patients with multiple organ metastases of colorectal cancer…
- Conditions
- Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT06449937
- Testing
- Radical local Surgery, Systemic therapy, Interventional therapy
- Where
- 6 sites in China
- Volunteers
- 130 people
- Sponsor
- Anhui Provincial Hospital
Recurrent Hepatocellular Carcinoma
Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion
The purpose of this study is to compare the treatment of recurrent hepatocellular carcinoma with repeat hepatectomy,and transcatheter arterial chemoembolization (TACE) with AFP conversion.
- Trial name
- HCCTACEAFP (NCT02728219)
- Testing
- TACE, Hepatectomy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCC
The goal of this observational study is to evaluate the safety and efficacy of systemic therapies and identify predictive molecular biomarkers in patients with intermediate to advanced stage or unresectable hepatocellular…
- Trial name
- MUSE2 (NCT07786792)
- Testing
- Systemic therapy, Local therapy
- Volunteers
- 400 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Cancer, Surgery
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
This observational clinical cohort study aims to evaluate the clinical utility of LiverMultiScan in quantifying liver health prior to liver resection or TACE.
- Conditions
- Liver Cancer, Surgery, Liver Regeneration, Colorectal Cancer Metastatic
- Trial name
- Hepatica (NCT03213314)
- Testing
- Multiparameter magnetic resonance imaging
- Where
- 2 sites in United Kingdom
- Volunteers
- 149 people
- Sponsor
- University of Edinburgh
Liver Cancer
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524316
- Testing
- doxorubicin hydrochloride, sunitinib malate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Hepatocellular Carcinoma (HCC), Liver Neoplasms
Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma
The goal of this prospective observational study is to validate the clinical utility of specific blood-based biomarkers for predicting and monitoring treatment response in patients with hepatocellular carcinoma (HCC) undergoing…
- Trial name
- BLOOD-TACE-M (NCT07414433)
- Where
- Serbia
- Volunteers
- 60 people
- Sponsor
- University of Belgrade
Hepatocellular Carcinoma, Adjuvant
Adjuvant TACE in HCC With High-risk Recurrence Factors
The 5-year recurrence rate after curative hepatectomy of hepatocellular carcinoma (HCC) remains as high as 70%. According to the Chinese Liver Cancer Staging (CNLC), transarterial chemoembolization (TACE) is strongly recommended…
- Conditions
- Hepatocellular Carcinoma, Adjuvant, Transarterial Chemoembolization
- Trial name
- NCT07417397
- Testing
- Adjuvant transarterial chemoembolization, Intensive follow-up
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Guangxi Medical University